449 related articles for article (PubMed ID: 21800888)
1. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
[TBL] [Abstract][Full Text] [Related]
2. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats.
Li F; Li QH; Wang JY; Zhan CY; Xie C; Lu WY
J Control Release; 2012 Apr; 159(2):261-70. PubMed ID: 22226772
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo.
Bansal R; Prakash J; De Ruiter M; Poelstra K
J Control Release; 2014 Apr; 179():18-24. PubMed ID: 24491909
[TBL] [Abstract][Full Text] [Related]
4. Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice.
Bansal R; Prakash J; Post E; Beljaars L; Schuppan D; Poelstra K
Hepatology; 2011 Aug; 54(2):586-96. PubMed ID: 21538439
[TBL] [Abstract][Full Text] [Related]
5. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.
Bansal R; Post E; Proost JH; de Jager-Krikken A; Poelstra K; Prakash J
J Control Release; 2011 Sep; 154(3):233-40. PubMed ID: 21664391
[TBL] [Abstract][Full Text] [Related]
6. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells.
Beljaars L; Molema G; Weert B; Bonnema H; Olinga P; Groothuis GM; Meijer DK; Poelstra K
Hepatology; 1999 May; 29(5):1486-93. PubMed ID: 10216133
[TBL] [Abstract][Full Text] [Related]
7. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.
van Beuge MM; Prakash J; Lacombe M; Gosens R; Post E; Reker-Smit C; Beljaars L; Poelstra K
J Pharmacol Exp Ther; 2011 Jun; 337(3):628-35. PubMed ID: 21383021
[TBL] [Abstract][Full Text] [Related]
8. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.
Bansal R; Prakash J; De Ruiter M; Poelstra K
PLoS One; 2014; 9(2):e89878. PubMed ID: 24587093
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth.
Bansal R; Tomar T; Ostman A; Poelstra K; Prakash J
Mol Cancer Ther; 2012 Nov; 11(11):2419-28. PubMed ID: 22933708
[TBL] [Abstract][Full Text] [Related]
10. The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells.
Li Q; Yan Z; Li F; Lu W; Wang J; Guo C
Nanotechnology; 2012 Jul; 23(26):265101. PubMed ID: 22700686
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier.
Prakash J; de Jong E; Post E; Gouw AS; Beljaars L; Poelstra K
J Control Release; 2010 Jul; 145(2):91-101. PubMed ID: 20362019
[TBL] [Abstract][Full Text] [Related]
12. Disease-induced drug targeting using novel peptide-ligand albumins.
Meijer DK; Beljaars L; Molema G; Poelstra K
J Control Release; 2001 May; 72(1-3):157-64. PubMed ID: 11389994
[TBL] [Abstract][Full Text] [Related]
13. Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern.
Ruehl M; Erben U; Kim K; Freise C; Dagdelen T; Eisele S; Trowitzsch-Kienast W; Zeitz M; Jia J; Stickel F; Somasundaram R
J Nutr Biochem; 2009 Aug; 20(8):597-606. PubMed ID: 18824344
[TBL] [Abstract][Full Text] [Related]
14. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver.
van Dijk F; Teekamp N; Beljaars L; Post E; Zuidema J; Steendam R; Kim YO; Frijlink HW; Schuppan D; Poelstra K; Hinrichs WLJ; Olinga P
J Control Release; 2018 Jan; 269():258-265. PubMed ID: 29170138
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats.
Adrian JE; Poelstra K; Scherphof GL; Meijer DK; van Loenen-Weemaes AM; Reker-Smit C; Morselt HW; Zwiers P; Kamps JA
J Pharmacol Exp Ther; 2007 May; 321(2):536-43. PubMed ID: 17314198
[TBL] [Abstract][Full Text] [Related]
17. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
Gonzalo T; Beljaars L; van de Bovenkamp M; Temming K; van Loenen AM; Reker-Smit C; Meijer DK; Lacombe M; Opdam F; Kéri G; Orfi L; Poelstra K; Kok RJ
J Pharmacol Exp Ther; 2007 Jun; 321(3):856-65. PubMed ID: 17369283
[TBL] [Abstract][Full Text] [Related]
18. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model.
Luk JM; Zhang QS; Lee NP; Wo JY; Leung PP; Liu LX; Hu MY; Cheung KF; Hui CK; Lau GK; Fan ST
Liver Int; 2007 May; 27(4):548-57. PubMed ID: 17403195
[TBL] [Abstract][Full Text] [Related]
19. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated.
Hagens WI; Mattos A; Greupink R; de Jager-Krikken A; Reker-Smit C; van Loenen-Weemaes A; Gouw IA; Poelstra K; Beljaars L
Pharm Res; 2007 Mar; 24(3):566-74. PubMed ID: 17245650
[TBL] [Abstract][Full Text] [Related]
20. The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue.
Beljaars L; Weert B; Geerts A; Meijer DK; Poelstra K
Biochem Pharmacol; 2003 Oct; 66(7):1307-17. PubMed ID: 14505810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
